Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

The healthcare IT market is driving digital transformation by enhancing efficiency, addressing workforce shortages, and ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

NovationSi, the manufacturing subsidiary for California-based R.D. Abbott Co. Inc., will supply the colorant for a cell ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...

Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...

Abbott’s device business has been a bright spot as litigation over its baby formula products and declining demand for its ...